Amber Specialty Pharmacy Added to Pfizer’s Limited Distribution Network for Oncology Portfolio

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces today that they will begin dispensing 13 Pfizer oncology products. The pharmacy’s comprehensive service model will support patients, caregivers, and oncology specialists throughout the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.

The Pfizer portfolio of oncology products now supported by Amber Specialty Pharmacy includes:

Besponsa® (inotuzumab ozogamicin)
Bosulif® (bosutinib)
Braftovi® (encorafenib)
Daurismo® (glasdegib)
Ibrance® (palbociclib)
Inlyta® (axitinib)
Lorbrena® (lorlatinib)
Mektovi® (binimetinib)
Mylotarg® (gemtuzumab ozogamicin)
Sutent® (sunitinib malate)
Talzenna® (talazoparib)
Vizimpro® (dacomitinib)
Xalkori® (crizotinib)

Amber Specialty Pharmacy is licensed to ship prescription medication to all 50 states in the U.S., as well as Puerto Rico.

For more information about Amber Specialty Pharmacy services, call [phone], or visit www.amberpharmacy.com.

About Amber Specialty Pharmacy

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with more than 23 years of experience providing specialized care for persons with chronic, complex medical conditions. Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families. This comprehensive care approach supports the medical, emotional, financial and administrative needs of patients throughout the United States. Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 18 locations throughout the United States and Puerto Rico. Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.